News that one of the most promising and advanced HIV vaccine trials has been halted has dealt a serious blow to global AIDS prevention efforts.

The vaccine’s developer, Merck, announced that it was ending enrollment and vaccination of volunteers in the US National Institutes of Health-funded study following a lack of evidence the vaccine had lowered the risk of HIV infection or reduced the severity of infection among volunteers who became infected during the trial.